Anti-EGFR-based maintenance versus stop and go in patients with left-sided, non-MSI-H, RAS/BRAF-wt metastatic colorectal cancer: individual patient data pooled analysis.

Fiche publication

Date publication

juin 2026

Journal

ESMO open

Auteurs

Membres identifiés du Cancéropôle Est :
Pr BOUCHE Olivier

Tous les auteurs :
Raimondi A, Tinè G, Boige V, De Stefano A, Ballhausen A, Gourgou S, Giuliani F, Stahler A, Randon G, Prisciandaro M, Manca P, Ambrosini M, Fazio R, Mohamed S, Gronchi G, Santabarbara G, Brument E, Alig AHS, Miceli R, Bouche O, Modest DP, Avallone A, Pietrantonio F

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/42269232

Résumé

Doublet chemotherapy plus an anti- epidermal growth factor receptor (EGFR) agent is a standard of care in patients with left-sided, microsatellite stable, RAS/BRAF wild-type (wt) mCRC. No conclusive evidence is available to guide treatment de-escalation, but several randomized clinical trials investigated either maintenance or intermittent treatment schedules (stop and go).